Trials / Completed
CompletedNCT01825122
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Invion, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with established chronic obstructive pulmonary disease (COPD) (chronic bronchitis dominant) or non-obstructive chronic bronchitis (NCB), compared to placebo and standard of care, while undergoing a validated smoking cessation program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nadolol | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-06-01
- Completion
- 2015-08-01
- First posted
- 2013-04-05
- Last updated
- 2017-02-01
- Results posted
- 2016-10-25
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01825122. Inclusion in this directory is not an endorsement.